Jacobs Levy Equity Management
KROS icon

Jacobs Levy Equity Management’s Keros Therapeutics KROS Stock Holding History

Jacobs Levy Equity Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.48M Sell
605,445
-100,626
-14% -$1.12M 0.02% 391
2026
Q1 		$7.8M Sell
706,071
-62,354
-8% -$963K 0.03% 343
2025
Q4 		$15.6M Buy
768,425
+161,336
+27% +$2.83M 0.06% 243
2025
Q3 		$9.6M Buy
607,089
+82,749
+16% +$1.22M 0.04% 307
2025
Q2 		$7M Buy
+524,340
New +$7.08M 0.03% 369

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management's KROS Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Keros Therapeutics (KROS) stake by 14% in Q2 2026, selling an estimated $1.12M and leaving 605,445 shares worth $6.48M. The position accounts for 0.02% of the portfolio, ranked #391.

Jacobs Levy Equity Management first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. The position peaked at $15.6M in Q4 2025. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jacobs Levy Equity Management held 605,445 shares of Keros Therapeutics worth $6.48M as of Q2 2026.
  • Jacobs Levy Equity Management sold 100,626 Keros Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Keros Therapeutics made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #391 holding.
  • Jacobs Levy Equity Management first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Jacobs Levy Equity Management's Keros Therapeutics position peaked at $15.6M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.